/JNJ
JNJ Stock - Johnson & Johnson
Healthcare|Drug Manufacturers - GeneralNYSE
$206.37-0.93%
$1.94 (-0.93%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).53
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1.7%upside
Target: $209.88
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JNJ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$204.31 – $208.43
TARGET (TP)$209.78
STOP LOSS$189.86
RISK/REWARD1:0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.35
52W High$215.19
52W Low$140.68
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B |
| Gross Profit | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B |
| Gross Margin | 69.1% | 68.8% | 69.3% | 70.3% | 65.6% |
| Operating Income | $22.15B | $23.41B | $21.01B | $20.94B | $19.73B |
| Net Income | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B |
| Net Margin | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% |
| EPS | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 |
Company Overview
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
52%
Hold / Neutral
10
48%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
11 Bullish10 Neutral/Bearish
Price Targets
$179
Average Target
↓ 13.0% Downside
Now
$150
Low
$179
Average
$230
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $230 |
| October 20th 2025 | Daiwa Securities | Upgrade | Outperform | $203 |
| October 3rd 2025 | Wells Fargo | Upgrade | Overweight | $212 |
| September 23rd 2025 | Guggenheim | Upgrade | Buy | $206 |
| July 23rd 2025 | Erste Group | Upgrade | Buy | - |
| May 13th 2025 | Leerink Partners | Downgrade | Market Perform | $153 |
| December 10th 2024 | BofA Securities | Resumed | Neutral | $166 |
| November 15th 2024 | Wolfe Research | Initiation | Outperform | $190 |
| July 23rd 2024 | Daiwa Securities | Downgrade | Neutral | $150← $160 |
| May 30th 2024 | Goldman | Resumed | Neutral | $160 |
| April 18th 2024 | HSBC Securities | Upgrade | Buy | $170 |
| December 13th 2023 | Wells Fargo | Downgrade | Equal Weight | $163← $170 |
| December 1st 2023 | UBS | Upgrade | Buy | $180← $167 |
| October 5th 2023 | RBC Capital Mkts | Initiation | Outperform | $178 |
| September 6th 2023 | HSBC Securities | Initiation | Hold | $175 |
Earnings History & Surprises
JNJBeat Rate
100%
Last 18 quarters
Avg Surprise
+4.6%
EPS vs Estimate
Beats / Misses
18/0
Last 12 quarters
Latest EPS
$2.80
Q4 2025
EPS Surprise History
Q1 24
+0.9%
$2.29vs$2.27
Q2 24
+2.7%
$2.71vs$2.64
Q3 24
+4.1%
$2.82vs$2.71
Q4 24
+9.5%
$2.42vs$2.21
Q1 25
+2.5%
$2.04vs$1.99
Q2 25
+7.4%
$2.77vs$2.58
Q3 25
+3.4%
$2.77vs$2.68
Q4 25
+1.4%
$2.80vs$2.76
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q1 2026 | Jan 21, 2026 | $2.53 | — | — | — |
Q4 2025 | Oct 14, 2025 | $2.76 | $2.80 | +1.4% | ✓ BEAT |
Q3 2025 | Jul 16, 2025 | $2.68 | $2.77 | +3.4% | ✓ BEAT |
Q2 2025 | Apr 15, 2025 | $2.58 | $2.77 | +7.4% | ✓ BEAT |
Q1 2025 | Jan 22, 2025 | $1.99 | $2.04 | +2.5% | ✓ BEAT |
Q4 2024 | Oct 15, 2024 | $2.21 | $2.42 | +9.5% | ✓ BEAT |
Q3 2024 | Jul 17, 2024 | $2.71 | $2.82 | +4.1% | ✓ BEAT |
Q2 2024 | Apr 16, 2024 | $2.64 | $2.71 | +2.7% | ✓ BEAT |
Q1 2024 | Jan 23, 2024 | $2.27 | $2.29 | +0.9% | ✓ BEAT |
Q4 2023 | Oct 17, 2023 | $2.52 | $2.66 | +5.6% | ✓ BEAT |
Q3 2023 | Jul 20, 2023 | $2.61 | $2.80 | +7.3% | ✓ BEAT |
Q2 2023 | Apr 18, 2023 | $2.51 | $2.68 | +6.8% | ✓ BEAT |
Q1 2023 | Jan 24, 2023 | $2.22 | $2.35 | +5.9% | ✓ BEAT |
Q4 2022 | Oct 18, 2022 | $2.49 | $2.55 | +2.4% | ✓ BEAT |
Q3 2022 | Jul 19, 2022 | $2.57 | $2.59 | +0.8% | ✓ BEAT |
Q2 2022 | Apr 19, 2022 | $2.60 | $2.67 | +2.7% | ✓ BEAT |
Q1 2022 | Jan 25, 2022 | $2.12 | $2.13 | +0.5% | ✓ BEAT |
Q4 2021 | Oct 19, 2021 | $2.37 | $2.60 | +9.7% | ✓ BEAT |
Q3 2021 | Jul 21, 2021 | $2.27 | $2.48 | +9.3% | ✓ BEAT |
Latest News
President Trump Says Johnson And Johnson And Four Other Companies Will Be Coming In Next Week, They've Agreed To Lowest Price In World
📈 PositiveBenzinga•Dec 19, 2025, 08:01 PM
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Goldman Sachs Maintains Buy on Johnson & Johnson, Raises Price Target to $240
📈 PositiveBenzinga•Dec 19, 2025, 05:01 PM
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralBenzinga•Dec 18, 2025, 04:27 PM•Also: , ,
Johnson & Johnson Receives FDA Approval For TRUFILL n‑BCA Liquid Embolic System In Symptomatic Chronic Subdural Hematoma
📈 PositiveBenzinga•Dec 18, 2025, 01:03 PM
Halozyme Says FDA Approves Johnson & Johnson's Five-Minute Injection Version Of Lung Cancer Drug RYBREVANT
📈 PositiveBenzinga•Dec 18, 2025, 12:07 PM•Also:
Reported Earlier, Johnson & Johnson Announces FDA Approval Of RYBREVANT FASPRO For EGFR Mutated NSCLC Delivering 5 Minute Administration And Supporting Chemo Free First Line RYBREVANT Plus LAZCLUZE
📈 PositiveBenzinga•Dec 18, 2025, 07:53 AM
FDA Proactively Awards National Priority Voucher Based On Strong Phase 3 Study Results
📈 PositiveBenzinga•Dec 15, 2025, 03:25 PM
Reported Friday, Johnson & Johnson Wins FDA Approval For AKEEGA In BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer, Cutting Radiographic Progression Or Death By 54%
📈 PositiveBenzinga•Dec 15, 2025, 08:03 AM
Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $197
📈 PositiveBenzinga•Dec 12, 2025, 05:25 PM
Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to $232
📈 PositiveBenzinga•Dec 11, 2025, 09:04 PM•Also:
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $230
📈 PositiveBenzinga•Dec 11, 2025, 03:25 PM
Reuters Issues Correction: U.S. FDA Says "Doing A Thorough Investigation, Across Multiple Age Groups, Of Deaths Potentially Related To Covid Vaccines"
📉 NegativeBenzinga•Dec 9, 2025, 08:54 PM•Also: , ,
Johnson & Johnson Announces New Data From Investigational Phase 3 Majestec-3 Study That Show Potential Of TECVAYLI Plus DARZALEX FASPRO As Early As Second Line For Patients With R/R Multiple Myeloma
📈 PositiveBenzinga•Dec 9, 2025, 12:48 PM
Johnson & Johnson Announced Saturday, Earlier Use Of CARVYKTI Demonstrated Lasting Treatment-Free Remissions At 2.5 Years In Patients With Relapsed Or Refractory Multiple Myeloma
📈 PositiveBenzinga•Dec 8, 2025, 01:07 AM
Johnson & Johnson Announces New Data From Investigational Cohort 4 Of Phase 2b SunRISe-1 Study Show Treatment With Gemcitabine Intravesical System Resulted In High One-Year DFS, PFS, And OS Rates In Patients With BCG-Unresponsive, High-Risk, Papillary-Only NMIBC
📈 PositiveBenzinga•Dec 5, 2025, 09:23 PM
Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $227
📈 PositiveBenzinga•Dec 5, 2025, 01:56 PM
Barclays Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $197
➖ NeutralBenzinga•Dec 2, 2025, 01:28 PM•Also:
FDA Grants Traditional Approval To Daratumumab And Hyaluronidase-fihj For Newly Diagnosed Light Chain Amyloidosis
📈 PositiveBenzinga•Nov 19, 2025, 05:51 PM
Johnson & Johnson falls after six-sessions of gain
➖ NeutralSeeking Alpha•Nov 18, 2025, 06:05 PM
Frequently Asked Questions about JNJ
What is JNJ's current stock price?
Johnson & Johnson (JNJ) is currently trading at $206.37 per share. The stock has moved -0.93% today.
What is the analyst price target for JNJ?
The average analyst price target for JNJ is $209.78, based on 1 analyst.
What sector is Johnson & Johnson in?
Johnson & Johnson operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is JNJ's market cap?
Johnson & Johnson has a market capitalization of $497.21 billion, making it a mega-cap company.
Does JNJ pay dividends?
No, Johnson & Johnson does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABBV
AbbVie Inc.
$226.72
Mkt Cap: $400.7B
AMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
AZN
AstraZeneca PLC
$91.36
Mkt Cap: $283.3B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
MRK
Merck & Co., Inc.
$101.09
Mkt Cap: $254.1B
NVO
Novo Nordisk A/S
$48.09
Mkt Cap: $213.8B
NVS
Novartis AG
$136.06
Mkt Cap: $266.2B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
UNH
UnitedHealth Group Incorporated
$327.42
Mkt Cap: $296.6B
Explore stocks similar to JNJ for comparison